What is Cree Gene?
Founded in 2016 and headquartered in Suzhou, China, Cree Gene is a biopharmaceutical technology firm specializing in the development of gene and cell therapy drugs. The company leverages advanced technologies, including gene editing, virus delivery systems, and macromolecular modification, to advance its therapeutic pipeline. Its focus on cutting-edge modalities positions it within the rapidly evolving landscape of precision medicine and genetic therapies.
How much funding has Cree Gene raised?
Cree Gene has raised a total of $77M across 2 funding rounds:
Series A
$17M
Series B
$60M
Series A (2018): $17M with participation from Qiming Venture Partners
Series B (2022): $60M, investors not publicly disclosed
Key Investors in Cree Gene
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology and healthcare. They aim to support entrepreneurs by providing industry resources and strategic guidance.
What's next for Cree Gene?
The substantial enterprise-level funding and recent strategic investment indicate Cree Gene is poised for accelerated expansion. This capital infusion is likely to fuel further research and development, clinical trial progression, and potentially the scaling of manufacturing capabilities. The company's trajectory suggests a move towards later-stage development and commercialization, aiming to bring its innovative gene and cell therapies to market.
See full Cree Gene company page
